7 Best Revenue Growth Stocks to Buy According to Analysts

2. Genmab A/S (NASDAQ:GMAB)

Average Price Target Upside: 56.20%

5-Year Revenue CAGR: 42.83%

Number of Hedge Fund Holders: 13

One of the best revenue growth stocks, Genmab A/S (NASDAQ:GMAB) is a biotechnology company based in Denmark that specializes in developing innovative antibody therapeutics aimed at treating cancer and other serious diseases.

Using advanced technology platforms, the company has built a strong pipeline that includes bispecific T-cell engagers, next-generation immune checkpoint modulators, and antibody-drug conjugates.

It has a clear vision to transform the treatment landscape by 2030 and seeks to deliver groundbreaking “Knock-Your-Socks-Off” antibody therapies to improve patient outcomes significantly.

Additionally, as per 26 analysts, the stock has a consensus Buy rating. As of September 27, the average price target of $38.00 implies an upside of 56.20% from the current levels.

A key factor in Genmab’s (NASDAQ:GMAB) success is its extensive network of partnerships, having established over 20 collaborations with leading biotech and pharmaceutical companies. The alliances enhance the company’s ability to accelerate the development of novel therapies.

In August, the company received conditional marketing authorization from the European Commission for TEPKINLY (epcoritamab), a treatment for adults with relapsed or refractory follicular lymphoma.

The approval is groundbreaking as TEPKINLY is the first and only subcutaneous bispecific antibody designed to engage T-cells for patients who have not responded to at least two prior therapies.

By effectively targeting and killing cancerous B-cells, TEPKINLY employs a unique mechanism that improves the body’s immune response against lymphoma. The innovative approach shows its focus on addressing unmet medical needs and the potential of its antibody therapies in the oncology space.

Furthermore, Genmab (NASDAQ:GMAB) has embraced technological advancements in its operations, recently rolling out an “AI Everywhere” initiative that has expanded access to AI tools for its employees. With over 2,000 licenses and more than 100 custom GPTs, the company is improving productivity and data analysis capabilities across various functions, from drafting documents to summarizing scientific literature.